Toronto, Ontario--(Newsfile Corp. - April 28, 2022) - Lophos Pharmaceuticals Corp., Lophos is a Canadian psychedelic research company focused on peyote and its derivatives such as mescaline. Peyote, an endangered plant species with a long history of therapeutic use has legal status in Canada, but mescaline, a powerful psychedelic molecule derived from the plant, remains a Schedule 3 controlled substance. At their facility, Lophos Pharma will research improved cultivation techniques, while evaluating a path to market for sustainably grown, peyote-based natural health products (NHPs).
"Our goal is to provide a sustainable source of peyote that is responsibly grown at our licensed facility," says Claire Stawnyczy, Founder and CEO of Lophos. "Lophos' mission is to protect this endangered species while developing innovative pharmaceutical treatments, harnessing alternative delivery techniques, and investing in peyote-derived natural health products."
Lophos is developing accelerated, responsible cultivation techniques which will reduce the peyote growth cycle and maintain the alkaloid content. Peyote's long growth cycle is one of the major challenges facing both researchers, and traditional cultivators.
Our current understanding of peyote and its applications in modern medicine is influenced by its traditional use within indigenous communities. It is important to Lophos Pharma to show respect to the plant, the indigenous communities that protect it, and the land it originates from. In an effort to reduce the negative impacts that peyote over-harvesting has had, Lophos Pharma is proud to establish an alternative source.
For more information please contact:
Alex Krause
Cushion Communications Inc.
alexkrause.pr@gmail.com
ABOUT LOPHOS
Lophos is a biosciences company that specializes in Peyote research, cultivation, preservation, and drug development. We develop novel therapies and natural health treatments that aim to restore and improve the quality of life for patients. Through advanced cultivation and harvesting techniques, Lophos Pharmaceuticals will provide our partners with medical grade inputs and our patients with access to safe and effective mescaline-based therapeutics.
Forward-Looking Statements
This press release contains 'forward-looking information' within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. Forward-looking information in this press release includes information with respect to the Company's psychedelics program. Forward-looking information is based on reasonable assumptions that have been made by the Company at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/121986
